Efficacy Of Shengjing Capsules For Treatment Of Male Infertility In China: A Systematic Review And Meta-Analysis

The aim of the current study was to evaluate the efficacy of Shengjing (Si) capsules for treatment of male infertility in China. Present researchers searched China National Knowledge Infrastructure (CNKI) database, Wanfang Database, VIP Science and Technology Periodical Database, China Biology Medicine Database (CBM), Cochrane library, PubMed, Embase, Clinicaltrails.org, and Chinese academic conference papers. Selection of randomized controlled trials (RCTs), before June 2018, was made concerning the effects of SJ capsule on male infertility, evaluated by Jadad scale scores. Data was analyzed with RevMan 5.3 and Stata/SE 14.1 software. A total of twenty-two randomized clinical trials (RCTs), involving 2,393 patients (1,201 patients in the trial group and 1,192 patients in the control group), were included. The total treatment risk ratio (RR) was 1.43 (95% IC: 1.29-1.60). Merged RRs of the single drug group and combined group were 1.70 (95% IC: 1.21, 2.39) and 1.34 (95% IC: 1.22, 1.46), respectively. Incidence of adverse events was low in all studies. SJ capsule are a new option for treatment of male infertility. However, high quality multi-centered, randomized, parallel-controlled, and blinded trials are necessary to confirm the safety and efficacy of SJ capsules. This requires further examination of treatment of male infertility with Si capsules.